Epidermal Growth Factor Receptor Inhibition With Erlotinib in Liver: Dose De-Escalation Pilot Trial as an Initial Step in a Chemoprevention Strategy

Epidermal Growth Factor Receptor Inhibition With Erlotinib in Liver: Dose De-Escalation Pilot Trial as an Initial Step in a Chemoprevention Strategy

Background and Aims: Effective approaches for prevention of hepatocellular carcinoma (HCC) will have a significant impact on HCC-related mortality. There are strong preclinical data and rationale to support targeting epidermal growth factor receptor (EGFR) for HCC chemoprevention. Small molecule inh...

Full description

Bibliographic Details
Main Authors: Kenneth K. Tanabe, David Zahrieh, Carrie A. Strand, Yujin Hoshida, Thomas J. Flotte, Gary Della’Zanna, Asad Umar, Kenneth D. Chavin, Sean Cleary, Naoto Kubota, Josep M. Llovet, Tushar Patel, Christopher Siegel, Paul J. Limburg
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Gastro Hep Advances
Subjects:
Erlotinib
Hepatocellular Carcinoma
Cirrhosis
EGFR
Prevention
Online Access:http://www.sciencedirect.com/science/article/pii/S2772572324000098

Internet

http://www.sciencedirect.com/science/article/pii/S2772572324000098

Similar Items